- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02110394
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia (NORMA)
July 4, 2016 updated by: Astellas Pharma Europe B.V.
Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
190
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Astrakhan', Russian Federation, 414056
- Alexandro-Mariinskaia Regional Clinical Hospital/13
-
Cherepovets, Russian Federation
- Vologda Reginal Clinical Hospital #2
-
Irkutsk, Russian Federation, 664079
- Irkutsk Regional Clinical Hospital/08
-
Kaliningrad, Russian Federation
- Kaliningrad City Clinical Hospital
-
Khabarovsk, Russian Federation, 630009
- Regional Clinical Hospital#1/04
-
Khanty-Mansiysk, Russian Federation
- District Cancer Center od Khanty -Mansiysk
-
Moscow, Russian Federation
- Central Clinical Hospital of Department of Presidential Affairs
-
Moscow, Russian Federation, 105203
- National Medical Surgical Center n.a.N.I.Pirogov/15
-
Moscow, Russian Federation, 115478
- RONC n.a.N.N.Blokhin/21
-
Moscow, Russian Federation, 129128
- Сentral Clinical Hospital n.a.N.A.Semashko/20
-
Moscow, Russian Federation
- Haematology Centre at Main Military Clinical Hospital n.a. N.N. Burdenko
-
Murmansk, Russian Federation, 183047
- Murmansk Regional Clinical Hospital n.a.P.A.Bayandin/31
-
Nizhniy Novgorod, Russian Federation, 603126
- Nizhniy Novgorod Regional Clinical Hospital n.a.N.A.Semashko/14
-
Obninsk, Russian Federation, 249036
- Medical Radiology Scientific Center/23
-
Omsk, Russian Federation
- Omsk Regional Clinical Hospital
-
Orenburg, Russian Federation, 460000
- Orenburg State Medical Academy/011
-
Perm, Russian Federation
- Perm regional hospital
-
Petrozavodsk, Russian Federation, 185019
- Karelia Republican Сlinical Hospital n.a.V.A.Baranov/32
-
Pskov, Russian Federation
- Pskov Regional Clinical Hospital
-
Rostov-on-Don, Russian Federation, 344037
- Rostov Scientific Research Oncology Institution/03
-
Saint-Petersburg, Russian Federation, 197758
- Military-Medical Academy n.a. Kirova
-
Saint-Petersburg, Russian Federation, 197341
- Site 70001 Private Practice
-
Samara, Russian Federation, 443099
- Samara State Medical University' Clinics/28
-
Saratov, Russian Federation
- Saratov State Medical University n.a. V.I.Razumovskiy
-
Smolensk, Russian Federation, 214025
- Road Clinical Hospital on Smolensk station OAO RZhD/12
-
Syktyvkar, Russian Federation, 167904
- Komi Republican Oncology Dispensary /01
-
Tula, Russian Federation, 300053
- Tula Regional Clinical Hospital/07
-
Tyumen, Russian Federation, 625023
- Tyumen Regional Clinical Hospital#1/27
-
Ul'yanovsk, Russian Federation, 432063
- Regional Clinical Hospital/26
-
Volgograd, Russian Federation, 400138
- Volgograd Regional Clinical Oncology Dispensary#1/25
-
Vologda, Russian Federation
- Vologda Regional Clinical Hospital
-
Yekaterinburg, Russian Federation
- Yekaterinburg Regional Clinical Hospital #1
-
Yekaterinburg, Russian Federation
- Yekaterinburg City Hospital #7
-
-
Ulan-Ude
-
Buryatia, Ulan-Ude, Russian Federation
- Republic Clinical Hospital n.a. N.A. Semashko
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with В-cell chronic lymphocytic leukemia under the care of a physician in the haematology/chemotherapy departments in 20-25 centers in the Russian Federation
Description
Inclusion Criteria:
- Patients with chronic lymphocytic leukemia (CLL) with current or planned first line therapy with Ribomustin
- Informed Consent Form for personal data handling signed by the program participant
Exclusion Criteria:
- Any prior chemotherapy and/or radiotherapy and/or immunotherapy and/or any investigational agent for treatment of CLL
- Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment
- Contraindications for Ribomustin usage in accordance with product label
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
bendamustine and rituximab
|
Routine practice
Other Names:
Routine practice
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate
Time Frame: Within 60-90 days after end of treatment
|
Within 60-90 days after end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 60 months
|
60 months
|
Adverse drug reactions
Time Frame: At all post-treatment visits (up to 30 days after end of treatment)
|
At all post-treatment visits (up to 30 days after end of treatment)
|
Treatment Failure (TF)
Time Frame: Within 60-90 days after end of treatment
|
Within 60-90 days after end of treatment
|
Time to Progression (TTP)
Time Frame: 60 months
|
60 months
|
Progression-Free Survival (PFS)
Time Frame: 60 months
|
60 months
|
Relapse following complete or partial remission
Time Frame: 60 months
|
60 months
|
Quality of Life of patients receiving Ribomustin therapy
Time Frame: At all post-treatment visits (up to 30 days after end of treatment)
|
At all post-treatment visits (up to 30 days after end of treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
April 8, 2014
First Submitted That Met QC Criteria
April 8, 2014
First Posted (Estimate)
April 10, 2014
Study Record Updates
Last Update Posted (Estimate)
July 6, 2016
Last Update Submitted That Met QC Criteria
July 4, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Bendamustine Hydrochloride
- Rituximab
Other Study ID Numbers
- RU-BEN-NI-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States